Establishment of a new human myeloma cell line (u-2030) and selection of a hat-sensitive subline

Publisher Website
Google Scholar
Abstract
We have established a new human myeloma cell line from the pleural effusion of a patient with an IgAλ myeloma, using special tissue culture conditions and selection procedures to prevent the outgrowth of contaminating Epstein‐Barr virus (EBV)‐carrying normal B‐lymphoblastoid cells present in the explant. The myeloma cell line, U‐2030, is aneuploid and EBNA‐negative and has morphological features, reactivity with cytochemical markers and cell‐surface antigen expression typical of plasmablasts. The cell line thus appears to be representative of the malignant clone in vivo. However, functionally the line is a non‐lg‐producer and must therefore be derived from a non‐secretory variant cell present within the highly aneuploid myeloma cell clone in vivo. The U‐2030 differs from previously established human myeloma cell lines in that it has a comparatively high growth rate, is clonable and can be made HAT‐sensitive relatively easily. This, together with the facts that it is a non‐lg‐producer and mycoplasma‐free, suggests that the 6‐thioguanine‐resistant, HAT‐sensitive subline, U‐2030 TG, derived from this cell line may be used as a malignant fusion partner for the production of human‐human hybridomas. An EBV‐carrying lymphoblastoid cell line (U‐2031) was also established. This line was diploid and had all the phenotypic properties of lymphoblastoid lines established from normal individuals.